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Puerto Rico
Roberto Abadie1*, Melissa Welch-Lazoritz1, Camila Gelpi-Acosta2, Juan Carlos Reyes3 and Kirk Dombrowski1
Abstract
Background: Blood contained in needles and injection equipment has been identified as a vector for HIV and HCV
transmission among people who inject drugs (PWID). Yet, there is often a wide discrepancy in prevalence for both
viruses. While microbiological differences between viruses influence prevalence, other variables associated with the
way drugs are acquired and used, also play a role.
Methods: Respondent-driven sampling (RDS) methods recruited a sample of 315 current intravenous drug users in
rural Puerto Rico. Information about type and frequency of use, HIV and HVC risk behaviors (sharing needles, cookers,
cotton, and water), sexual behaviors, and alcohol use was collected. HIV and HCV statuses were assessed via rapid
antibody tests. T tests compare means of participants who tested positive (reactive) to those who tested negative.
Logistic regression analyses were used to validate the association of the risk factors involved.
Results: Tests showed a significant difference in HIV (6 %) and HCV (78.4 %) prevalence among a population of current
PWID. The main risk behaviors in HCV transmission are the sharing of injection “works”, (e.g., cookers, cotton, and water).
Sharing works occurred more than twice as often as the sharing of needles, and HCV+ and HCV− individuals reported the
same needle sharing habits.
Conclusions: Washing and rinsing injection works with water seems to prevent HIV transmission, but it is unable
to prevent HCV infection. While education about the need to clean injection equipment with bleach might be
beneficial, equipment sharing—and the subsequent risk of HVC—might be unavoidable in a context where participants
are forced to pool resources to acquire and use intravenous drugs.
Keywords: HIV-HCV risk factors, PWID, Sharing, Injection equipment, Rural Puerto Rico
Background
The current 2015 study of people who inject drugs
(PWID) in rural Puerto Rico found that 6.0 % of the
sample was HIV positive while 78.4 % of the sample was
Hepatitis C (HCV) positive using rapid tests. Research
has shown that PWID in Puerto Rico are at a very high
risk for HIV, as injection drug use is the most important
factor behind the prevalence of HIV on the island [1–4].
Puerto Rico occupies the sixth place in HIV prevalence
among all US states and territories [5]. Injection drug
use is responsible for almost half of the accumulated
AIDS cases and nearly 26 % of HIV cases diagnosed
between 2005 and 2011. In 2010, PWID accounted for
8.6 % of new HIV infections across the USA, while the
proportion in Puerto Rico was over two times greater
(20.4 %) [6]. A study by Reyes et al. among PWID in the
metropolitan San Juan area places HIV prevalence at
17 % and HCV prevalence at a striking 89 % [7].
Studies have documented wide discrepancies in the
prevalence of HIV and HCV among PWID across the
world [8, 9]. Research has identified the main causes of
transmission for both viruses as blood contained in the
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syringes, cookers, cotton, and water [10, 11]. Still, PWID
appear to be more vulnerable to HCV than to HIV. The
microbiological properties of HCV are considered one of
the main reasons behind these prevalence discrepancies
[12]. Indeed, HCV is more potent and resilient than the
HIV virus and can live on surfaces of the body for up to
6 weeks while maintaining infectivity [13, 14]. Years of
injection, using in shooting galleries, incarceration, num-
ber of injection partners, and history of sexually trans-
mitted diseases have been associated with higher rates of
HCV acquisition among PWID [15–17]. In Puerto Rico,
lack of knowledge of the HCV and lack of awareness of
HCV serostatus have also been identified as factors
behind transmission [18].
Various researchers [19, 20] have suggested that the
sharing of injection equipment, such as cookers and cotton,
could be contributing to HCV transmission vulnerability
for PWID. Indeed, many argue that PWID may be sharing
cookers, cottons, and water more often than they are shar-
ing syringes, and this is particularly true since the advent of
needle exchange programs in the USA [21]. Another study
with PWID in Denver, CO, found that while just 22 % of
users shared needles, 86 % used a common cooker to divide
drugs [22].
Our study seeks to explore these risk factors among
rural Puerto Rican PWID, a population whose risk behav-
iors have never before been studied, perhaps due to the
difficulties of accessing a marginalized population. We
also aim to contribute to the literature by comparing the
risk behaviors of HCV positive and HCV negative PWID
in rural Puerto Rico. By outlining the similarities and
differences in risk behaviors between these two groups, we
will help identify the service needs to be addressed to
arrest the further spread of HCV among PWID in
Puerto Rico and abroad.
Methods
Data
This paper utilizes data from 315 PWID residing in Cidra,
Comerio, Aguas Buenas, and Cayey, four rural towns in the
mountainous area of central Puerto Rico, about 30–40 miles
from San Juan. Sites were selected because they were repre-
sentative of rural PWID on the island [23]. In addition,
these sites were chosen due to the presence of El Punto en
la Montaña, the only syringe exchange program operating
in rural Puerto Rico, with whom we established a close
collaboration that facilitated data collection with this
population. Interviews were completed between April
2015 and June 2015. Sample recruitment was managed
using respondent-driven sampling (RDS) and we started
two seeds in each of the four towns (for a total of 8
seeds, 307 recruits). Participants who completed the
survey were given three referral coupons to pass out to
other PWID they knew and who had not previously
participated in the study. Every eligible referral earned
the recruiter an additional $10. Upon completion of the
questionnaire, participants were given $25. RDS has
proven effective in recruiting hard to reach populations
[24–27]. Participants were 18 years of age or older, alert
at the time of the interview, and had injected drugs
within the past 30 days. Verification of current injec-
tion use was done through visual inspection of injection
track marks as well as through a questionnaire that
measuring knowledge of injection practices [28, 29].
The questionnaire was interviewer-administered and
based off of the CDC NHBS IDU Round 3 Questionnaire
version 13. In addition to demographic variables, we col-
lected information about type and frequency of drug use,
as well as HIV and HCV risk behaviors such as sharing of
needles, cookers, cotton, and water in addition to sexual
behaviors and alcohol use. HIV and HCV status was
assessed through the use of INSTI Rapid HIV antibody
tests (Biolytical Laboratories) and OraQuick HCV Rapid
antibody tests (OraSure Technologies). Every participant
was compensated an additional $5 for each rapid test
performed. Participants who tested positive for HCV or
HIV were offered referral and transportation to a primary
care doctor for confirmatory testing. The study received
IRB approval through the University of Nebraska-Lincoln
(IRB# 20131113844FB) and the University of Puerto Rico
School of Medicine (IRB# A8480115).
Measures
HIV status and HCV status were determined by the
results of the INSTI Rapid HIV and OraQuick Rapid
HCV test. Annual per capita income was assessed by
two questionnaire items, one which participants selected
an income bracket and a second which participants re-
ported how many people rely on that income during the
year. The upper limit of the income bracket was then di-
vided by the number of people relying on income to
achieve an approximation of annual per capita income.
Percent unemployed was assessed using a question that
asked participants which best described their employ-
ment status: employed full time, employed part time, full
time student, retired, unable to work for health reasons,
unemployed, or other.
Frequency of injection was assessed using the question
“in the last 12 months, on average, how often did you in-
ject drugs?” with response choices of (1) one time per
month, (2) 2–3 times per month, (3) one time per week,
(4) 2–6 times per week, (5) one time per day, (6) 2–3 times
per day, and (7) 4 or more times per day. Number of people
used needle is a continuous measure based on the question
“with how many people did you use a needle after they
injected with it?”, this question was framed in the context
of both “in the past 12 months” and “in the past month”.
Number of people used works is also a continuous measure
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from the question “with how many people did you use the
same cooker, cotton, or water that they had already used?”
with responses for past year and past month. Number of
people backloaded is a continuous measure assessing with
how many people the participant used drugs that had
been divided with a syringe that they had already used
(i.e., backloading, frontloading), in the past year and in
the past month.
Frequency of (1) used needle utilization, (2) used cooker
utilization, (3) used cotton utilization, and (4) used
water utilization are four categorical measures asking
how often, in the past year, the participant used (1) needles
that someone else had already injected with, (2) a cooker
that someone else had already used, (3) a cotton that some-
one else had already used, and (4) water that someone else
had already used. The response options are never (coded as
0), rarely (coded as 1), about half of the time (coded as 2),
most of the time (coded as 3), and always (coded as 4).
Analytic approach
Analysis of the RDS data was undertaken using both of the
current, accepted RDS analysis platforms: RDSAT version
7.1 [30] and RDS Analyst [31]. No significant differences in
results were found between the two routines. Dual homo-
phily scores were calculated for the main demographic
variables, including gender, age, HIV and HCV status, drug
treatment participation, drug choice, number of sex part-
ners, geographic location of recruitment, frequency of drug
use, income, and homelessness in the past year. For the
demographic variables (age, gender, income, location, and
homeless status), no significant biases were discovered.
Complex homophily results were found for individual vari-
able values on drug of choice (only use of speedball was
significant, other drugs were not), HCV status (only known
positive status was significant) and treatment participation.
As none of these influenced the demographic variables, the
analyses discussed here were made from sample point esti-
mates, unadjusted by RDS results. A full discussion of the
RDS sample and its analysis is currently under review in
the Puerto Rican Public Health Sciences Journal.
The results reported in this analysis stem from t tests to
compare the means of participants who tested positive
(reactive) for HCV antibodies in the rapid test, and partici-
pants who tested negative for HCV antibodies on several
variables, including injection habits. Multivariate analyses
using logistic regression were used to further evaluate the
association of risk factors shown in the comparison of
means tests. We conducted a logistic regression with each
variable tested in Table 2 and controlled for gender (male),
age, per capita income, education level (high school gradu-
ate or better), marital status (married or cohabiting), and
number of years spent injecting drugs. All analyses were
conducted using IBM SPSS Statistics software.
Results
Table 1 presents demographic data for study participants.
More than three quarters (78.4 %) tested positive for HCV
during the rapid test, while 6.0 % tested positive for HIV.
All 19 HIV positive participants were HCV co-infected.
Approximately 90.5 % (n = 285) were male and 93.0 %
were born in Puerto Rico. Almost all PWID who were not
born in Puerto Rico had been born in the continental
United States. The sample had a mean age of 41.8 years
(range 18–70 years) and an average annual per capita
income of $4452. Participants were mostly (85.4 %) un-
employed, 21.9 % were homeless at the time of their inter-
view, and 52.4 % were high school graduates (or higher).
Only 2.9 % of participants were currently married, though
an additional 19.3 % were living together as married, while
47 % were single and never married (the remaining 30.8 %
were separated, divorced, or widowed).
As shown in Table 2, commonalities in injection
behaviors regardless of HCV status are apparent. For in-
stance, both groups reported injecting drugs at the same
average frequency during the past year. In addition, past
year utilization of used needles and the number of
people who used needles before them are exactly the
same. However, significant differences between HCV
statuses shed some light over the vast disparity between
HIV and HCV infection found in rural Puerto Rico. First,
HCV+ injectors are, on average, 3 years older than their
HCV− counterparts (p ≤ .031). Second, those who were
HCV+ began injecting drugs at a much younger age
(20.7 years) than those HCV− participants (26.3 years;
p ≤ .001); and third, HCV+ participants have spent 9.4
more years injecting drugs than their HCV− counter-
parts (p ≤ .001).
Importantly, marked differences in their use of works
are of note. Specifically, HCV+ participants used injection
preparation equipment (cooker, cotton, and/or water)
after an average of almost 2 more people in the past year
Table 1 Descriptive statistics
Mean/% SD N
% HIV positive (INSTI Rapid Test) 6.0 % 315
% HCV positive (OraQuick Rapid Test) 78.4 % 315
% Male 90.5 % 315
% Born in Puerto Rico 93.0 % 315
Age (years) 41.8 (10.07) 315
Annual per capita income $4452 ($3200) 311
% Unemployed 85.4 % 314
% Currently homeless 21.9 % 314
% Graduate high school (or higher) 52.4 % 315
% Married or living together as married 22.2 % 315
% Injected 4 or more times per day 39.7 % 315
% Injected 2–3 times per day 39.7 % 315
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than their HCV− counterparts (4.9 people compared to
3.0 people, p ≤ .122; though not significant at standard p
values, this large difference is notable). In the past year,
HCV+ participants backloaded after an average of .6 more
people (p ≤ .086) and injected with a used cooker signifi-
cantly more frequently (p ≤ .034) than HCV− participants.
In the past month, HCV+ injectors used works after 1
more person than those without HCV (p ≤ .001).
After controlling for gender, age, annual per capita
income, marital status, and level of education, the sig-
nificance of the results from the comparison of means
holds up (the entire logistic regression table is available
online as Additional file 1 to this paper). Logistic regres-
sion results indicate that for every one-unit increase in the
frequency of past year used cooker utilization, there is a
26 % increase in the odds of being HCV+ (p ≤ .029). Each
additional person who used works before the participant
during the past month is associated with an 18 % increase
in the odds of being HCV+ (p ≤ .039). Interestingly, no
measurements of needle sharing behaviors were statisti-
cally significant predictors of HCV.
The number of people who used works before a partici-
pant in the last year (4.9 HCV+ and 3.0 HCV−) is more
than double (or quadruple for HCV+ injectors) the num-
ber of people who used a needle before a participant in
the past year (1.2 for both HCV+ and HCV−). Similarly,
the past year frequency of injecting with a used cooker
was at least double that of injection with a used needle.
Clearly, needle sharing was not the main mechanism for
HCV transmission among rural Puerto Rican PWID.
Discussion
This study found an HIV prevalence of 6 % and an HCV
prevalence of 78.4 % among a sample of intravenous drug
users in rural Puerto Rico. This prevalence for HCV is
among the highest in the world [32–35]. A systematic re-
view of 77 countries found a mid-point prevalence esti-
mate for HCV among PWID between 60 and 80 % in 25
countries and more than 80 % in 12 countries [36].
Our results indicate that HCV risk lies in sharing
works, or specifically cookers, and this could be espe-
cially problematic for disease contraction because of
HCV’s ability to live outside the body for many days
[37], and its ability to spread with only a very small con-
centration of blood that could be found in drug using
equipment, even after rinsing with clean water [38]. Age,
the number of people who had used works before the
participant, and frequency of used cooker utilization are
all significantly higher for individuals with HCV. While
sharing needles, cookers, cotton, and water has been
outlined as a main risk for both HIV and HCV, our
study shows that the main risk for HCV infection, given
current behaviors, is associated with sharing cookers
more than with using needles after somebody else had
used them. This builds upon research [39–42] showing
that an important proportion of HCV infections are
likely attributable to cooker or cotton sharing.
Sharing works could very well be related to the rural in-
jectors’ needs to pool resources to acquire the drugs. The
most commonly injected drug for our sample is speedball,
a mix of heroin and cocaine, and most participants inject
Table 2 Comparison of means for injecting practices by HCV status
HCV+(n = 247) HCV−(n = 68) N
Age (years) 41.8* 38.8* 315
Age at first use of injection drugs 20.7*** 26.3*** 315
# of years injecting drugs 21.9*** 12.5*** 315
Past year:
Frequency of injection 5.9 5.9 315
# of people used needle 1.2 1.2 314
# of people used works 4.9 3.0 314
# of people backloaded 1.5 0.91 311
Frequency of used needle utilization 0.4 0.4 315
Frequency of used cooker utilization 1.1* 0.8* 315
Frequency of used cotton utilization 0.8 0.6 315
Frequency of used water utilization 0.7 0.5 315
Past month:
# of people used needle 0.4 0.5 315
# of people used work 2.0** 1.0** 315
# of people backloaded 0.6 0.5 313
*p < .05, **p < .01, ***p < .001
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multiple times per day. In the four municipalities where
study participants reside, the approximate cost of a small
bag of heroin is $6, and $5 for a small bag of cocaine, thus
requiring $11 for one single injection event. One means to
deal with this is to pool resources and share the drugs.
Further, speedball use is often associated with high fre-
quency of injection [43]. This represents a significant
challenge for the current sample of rural Puerto Rican
injectors, who have an average per capita annual income of
just $4452. When sharing, users mix the purchased heroin
and cocaine bags in the same cooker before injecting. In
fact, this practice is commonly called “caballo”, or horse, in
rural Puerto Rico. Once the drug is dissolved in the cooker,
injectors can collect their “share” via separate or shared
syringe, taking turns. Others might prefer to backload.
Dissolving the pooled drug in the same cooker may also
be leading participants to using the same cotton to filter
the drug.
In addition to the hardy virological properties of HCV,
another factor contributes to the epidemic is lack of
HCV treatment. While 82.5 % of our sample has state
sponsored health insurance coverage (Reforma), many
are unable to access HCV treatment, as the state health
insurance plan will not cover this expensive treatment
unless the patient is also HIV positive. Barriers to HCV
treatment in the island have been also previously described
[44] and as such, the vast majority of HCV patients carry
the virus for many years [45].
Finally, interventions designed to provide more education
to PWID about the particular viral characteristics of HCV
and its strong transmission risk would be beneficial. Other
strategies to reduce the prevalence of HCV among this
population include more extensive testing and counseling,
along with efforts to scale up HCV treatment for those that
have tested positive to HCV, especially in resource-rich
countries [46, 47]. However, while these interventions, as
well as other more general harm reduction strategies like
providing safe injection rooms [48] or extending the pres-
ence of needle exchange programs [49, 50] are advisable,
the financial incentive to pool resources to jointly acquire
and use the drugs continues to be a significant obstacle to
curb the spread of HCV in this population. Furthermore,
migration patterns, especially across borders, might compli-
cate prevention efforts by making PWID harder to reach,
or by introducing the risk of HIV/HCV infection in other
social networks [51, 52].
Limitations
One limitation resides in the fact that while RDS is a
standard methodology for reaching marginalized popula-
tions, we cannot be sure that our sample completely ac-
counts for the entire population of rural injectors. Another
constrain is that this study asked participants about fre-
quency of drug use at different intervals, spanning from
the past month, to the past year. It is not possible to ex-
clude the possibility of recall bias, especially when partici-
pants are asked to remember information from practices
far removed from the present. Despite this limitation, we
believe that probing participant about drug frequency at
different time intervals is justified by the need to document
potential changes in drug use patterns over time. This
study is further limited in its reliance on self-reports rather
than observed risk behaviors. While asking participants
about their risk practices illuminates the risks they face in
the course of injecting drugs, it remains a less precise alter-
native when compared with directly observing these same
behaviors. The interpretation of data about co-infection of
HIV and HCV is limited because our survey did not collect
temporal data about which infection came first, obscuring
the fact that PWID living with HIV (n = 19) are more likely
to contract HCV.
Conclusions
The wide discrepancy in prevalence between HIV and
HCV among PWID in rural Puerto Rico does not have a
single explanation. Nevertheless, this study found consider-
able evidence that HCV transmission is occurring in associ-
ation with the shared use of contaminated cookers, cotton,
and water, rather than via syringes. Future research should
consider studying HCV infectivity in injection works, like
cookers and cottons, following Paintsil et al.’s 2010 study
on HCV infectivity in low and high volume syringes [14].
Also, HCV education might not overcome participants’
needs to pool resources. Finally, adding health insurance
coverage for HCV treatment, and particularly so for impo-
verished Puerto Ricans, might help improve HCV screening
and testing, diminishing the pool of HCV-infected PWID
and, in turn, slowing the spread and lowering the overall
prevalence of HCV among this population.
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